{"name":"Stichting Hemato-Oncologie voor Volwassenen Nederland","slug":"stichting-hemato-oncologie-voor-volwassenen-nederland","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"DA-EPOCH-R followed by Nivolumab","genericName":"DA-EPOCH-R followed by Nivolumab","slug":"da-epoch-r-followed-by-nivolumab","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_2"},{"name":"Daunorubicin or Idarubicin","genericName":"Daunorubicin or Idarubicin","slug":"daunorubicin-or-idarubicin","indication":"Acute myeloid leukemia (AML)","status":"phase_3"},{"name":"Placebo for AG-120","genericName":"Placebo for AG-120","slug":"placebo-for-ag-120","indication":"Acute myeloid leukemia","status":"phase_3"},{"name":"Placebo for AG-221","genericName":"Placebo for AG-221","slug":"placebo-for-ag-221","indication":"Control arm in phase 3 trial for acute myeloid leukemia (AML) with IDH2 mutations (AG-221 indication)","status":"phase_3"},{"name":"Venetoclax 400","genericName":"Venetoclax 400","slug":"venetoclax-400","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"}]}],"pipeline":[{"name":"DA-EPOCH-R followed by Nivolumab","genericName":"DA-EPOCH-R followed by Nivolumab","slug":"da-epoch-r-followed-by-nivolumab","phase":"phase_2","mechanism":"DA-EPOCH-R is a chemotherapy regimen that combines etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide, followed by Nivolumab, a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Classical Hodgkin lymphoma"],"catalyst":""},{"name":"Daunorubicin or Idarubicin","genericName":"Daunorubicin or Idarubicin","slug":"daunorubicin-or-idarubicin","phase":"phase_3","mechanism":"Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA damage and cancer cell death.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Chronic myeloid leukemia (CML) in blast crisis"],"catalyst":""},{"name":"Placebo for AG-120","genericName":"Placebo for AG-120","slug":"placebo-for-ag-120","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":["Acute myeloid leukemia"],"catalyst":""},{"name":"Placebo for AG-221","genericName":"Placebo for AG-221","slug":"placebo-for-ag-221","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":["Control arm in phase 3 trial for acute myeloid leukemia (AML) with IDH2 mutations (AG-221 indication)"],"catalyst":""},{"name":"Venetoclax 400","genericName":"Venetoclax 400","slug":"venetoclax-400","phase":"phase_3","mechanism":"Venetoclax is a small molecule inhibitor of the BCL-2 protein, which is involved in apoptosis regulation.","indications":["Chronic lymphocytic leukemia (CLL)","Acute myeloid leukemia (AML)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9Cd3ViaER2SzB5bG5PdjkwajZObFRDOVNvQnBkLU54SDhlVWlSYU5qWnRJN3puMkp5Rmp1eG10eEJDenEzV0RUNkVMa3d2Sm9uOS1vaVRpZUVSdXBxb2taeW5zMkNBd2wzaERrLUhpVWtNejdBcFRmZQ?oc=5","date":"2025-03-10","type":"trial","source":"Oncology Pipeline","summary":"J&J catches its menin rivals | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"J&J catches its menin rivals | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":1,"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}